DRAGARWQ · NSE
Dr Agarwals Eye Hospital Limited
₹5,269.5
+2.58% (+₹132.5)
Prev. close
₹5,137
Volume
3,151
Delivery %
84.8%
As of
16 Sept 2026
Price history
No analyst calls on this stock in the last 90 days yet.
Explore by date range →Analyst opinions
Fundamentals
About Dr Agarwals Eye Hospital Limited
Dr. Agarwal's Eye Hospital Limited engages in the provision of eye care and related services in India, Ghana, Uganda, Kenya, Madagascar, Tanzania, Rwanda, Zambia, Mozambique, and Mauritius. The company, through its hospitals, offers services in the areas of cataract, glaucoma, laser correction, cornea and refractive, retina, squint, corneal ulcer, fungal keratitis, diabetic retinopathy, retinal detachment, nystagmus, ptosis, conjunctivitis, retinopathy prematurity, macular hole and edema, cornea transplantation, behcets, computer vision syndrome, hypertensive retinopathy, black fungus, traumatic cataract, keratoconus, uveitis, pterygium, blepharitis, posterior subcapsular cataract, pinhole pupilloplasty, rosette cataract, and congenital glaucoma. It also operates opticals and pharmacies and is engaged in the sale of optical frames, contact lenses, accessories, and pharmaceutical products. Dr. Agarwal's Eye Hospital Limited was founded in 1957 and is based in Chennai, India. Dr. Agarwal's Eye Hospital Limited operates as a subsidiary of Dr. Agarwal's Health Care Limited.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Dr. Adil Agarwal M.B.B.S, M.S, MBA
Headquarters
Chennai
Employees
1,356
Website
dragarwal.comExchange
View on NSE ↗Key stats
P/E ratio (TTM)
33.2
EPS (TTM)
₹158.73
Beta (5Y monthly)
-0.52
Shares float
10.87 L
EPS · quarter ended Jun 2026
₹48.38
Financial Performance
01 · Financials
Revenue for Mar 2021–Mar 2022 is as filed with BSE (standalone), and the first plotted growth figure is computed against Mar 2020 revenue as filed with BSE; the two sources' revenue definitions differ by 0.4% on Mar 2023. FY22 growth needs FY21 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹139.81 Cr | ₹201.22 Cr | ₹266.73 Cr | ₹316.54 Cr | ₹393.90 Cr | ₹469.62 Cr | |
| EBITDA | ₹31.18 Cr | ₹58.94 Cr | ₹76.38 Cr | ₹95.96 Cr | ₹122.51 Cr | ₹151.08 Cr |
| ₹-1.44 Cr | ₹24.11 Cr | ₹36.92 Cr | ₹46.36 Cr | ₹54.65 Cr | ₹70.10 Cr | |
| Diluted EPS | ₹-3.06 | ₹51.29 | ₹78.55 | ₹98.64 | ₹116.28 | ₹147.02 |
Depreciation & amortisation, Pretax income, Tax provision, Interest expense have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
09 · Balance Sheet
Annual
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|
| — | ₹155.23 Cr | ₹314.01 Cr | ₹389.94 Cr | ₹495.76 Cr | ₹613.32 Cr | ₹766.46 Cr | |
| — | ₹67.55 Cr | ₹193.46 Cr | ₹232.47 Cr | ₹268.02 Cr | ₹333.16 Cr | ₹326.13 Cr | |
| Stockholders' equity | — | ₹54.66 Cr | ₹78.17 Cr | ₹113.34 Cr | ₹157.15 Cr | ₹209.61 Cr | ₹346.30 Cr |
Total assets, Current assets, Trade receivables, Cash & equivalents, Non-current assets, CWIP, Others, Total debt, Long-term debt, Current (short-term) debt, Stockholders' equity have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| — | — | ₹69.62 Cr | ₹89.77 Cr | ₹93.56 Cr | ₹145.14 Cr | |
| Investing cash flow | — | — | ₹-70.61 Cr | ₹-70.04 Cr | ₹-132.78 Cr | ₹-173.53 Cr |
| — | — | ₹26.00 L | ₹-14.23 Cr | ₹16.58 Cr | ₹24.78 Cr | |
| Capital expenditure | — | — | ₹-70.34 Cr | ₹-71.32 Cr | ₹-102.86 Cr | ₹-98.39 Cr |
| End cash position | — | — | ₹27.38 Cr | ₹32.88 Cr | ₹10.24 Cr | ₹6.63 Cr |
Operating cash flow, Depreciation & amortization, Change in working capital, Investing cash flow, Financing cash flow, Debt issued, Debt repaid, Dividends paid, Capital expenditure, End cash position have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Dr Agarwals Eye Hospital Limited | — | ₹5,269.5 | 32.4 | — | 20.2% | 0.94 | +19.2% | — |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
Annual reports
Show all 28
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
1 index
Weight is BSE’s own published index weight. Indices without weight data are listed without one, in alphabetical order after the weighted ones.